The Foundations of the R&D Tax Credit Framework

The legislative intent behind both the United States federal and Connecticut state Research and Development tax credits is the stimulation of domestic technological innovation and the preservation of high-skilled employment. For corporate entities situated in Hartford, Connecticut, navigating this landscape requires reconciling the stringent criteria of the Internal Revenue Code (IRC) with the highly specific, multi-tiered incentive structures administered by the Connecticut Department of Revenue Services (DRS). The federal framework, codified under IRC Section 41, provides a baseline mechanism for calculating Qualified Research Expenses (QREs), while Connecticut’s dual-statute system under Connecticut General Statutes (CGS) Sections 12-217j and 12-217n offers both incremental and non-incremental relief, supplemented by aggressive cash-exchange provisions for qualifying small businesses and biotechnology firms.

Before expenditures can be evaluated for the Section 41 credit, they must qualify as research and experimental expenditures under IRC Section 174. Historically, Section 174 allowed taxpayers to immediately deduct these expenses in the year they were incurred. However, following the enactment of the Tax Cuts and Jobs Act (TCJA), taxpayers are now required to capitalize and amortize domestic Section 174 expenses over a five-year period, and foreign expenses over a fifteen-year period, effective for tax years beginning after December 31, 2021. This structural shift has profoundly impacted corporate cash flow, elevating the strategic importance of claiming the Section 41 credit—and the corresponding state credits—to offset tax liabilities and generate non-dilutive capital. To be classified as QREs under Section 41, the expenditures must generally consist of wages paid to employees for qualified services, the cost of supplies consumed in the conduct of qualified research, or amounts paid to third parties for the right to use computers in the research process.

The Internal Revenue Service (IRS) strictly mandates that all claimed activities independently satisfy a rigorous four-part test, applied separately to each specific business component, which may include a product, process, computer software, technique, formula, or invention.

The State of Connecticut leverages this federal baseline but implements its own distinct corporate business tax credit mechanisms. Under CGS § 12-217j, Connecticut provides a 20 percent credit on the incremental increase in research and experimental expenditures conducted within the state during the current income year over the amount spent in the preceding income year. Excluded from this are overhead costs, general administrative expenses, routine quality control testing, and consumer surveys. Concurrently, CGS § 12-217n provides a non-incremental, rolling tax credit based on total annual R&D spending within the state.

A Qualified Small Business (QSB) in Connecticut is statutorily defined as a company with gross income in the previous income year that does not exceed $100 million, provided it has not met this threshold through transactions with related persons. Furthermore, the Connecticut legislature has instituted specific parameters regarding the utilization of these credits. While historical credits could be carried forward indefinitely, legislation enacted in 2021 mandates that any unused credits earned in income years commencing on or after January 1, 2021, are subject to a maximum carryforward period of fifteen years. Additionally, the maximum corporate tax liability that can be offset by these credits was systematically increased from 50.01 percent to 60 percent for the 2022 income year, and ultimately to 70 percent for the 2023 income year and thereafter.

The following sections dissect six critical industries that define Hartford’s economic landscape. By examining the historical development of each sector, this study evaluates how prototypical Hartford-based enterprises can substantiate their eligibility under evolving federal case law and specific Connecticut DRS administrative guidance.

Case Study: The Insurance and InsurTech Ecosystem

The designation of Hartford as the “Insurance Capital of the World” is the result of centuries of economic evolution, originating from its 18th-century status as a vital Connecticut River port. The city served as a primary conduit for goods moving between New England, Europe, and the West Indies. To mitigate the profound financial risks of maritime trade, river captains and affluent merchants routinely gathered in Hartford coffee houses to informally syndicate voyage risks. This localized risk-sharing formalized in 1794 when merchant Jeremiah Wadsworth began offering rudimentary fire insurance. By 1810, the Connecticut General Assembly chartered the Hartford Fire Insurance Company, established by local civic leaders with $15,000 in working capital to protect urban property against catastrophic fires.

Hartford’s insurers distinguished themselves not merely through capital formation, but through an unwavering commitment to solvency during national crises. Following the devastating New York City fires of 1835 and 1845, the Chicago fire of 1871, and the 1906 San Francisco earthquake, Hartford-based firms honored their claims promptly while many regional competitors defaulted. This reputation catalyzed exponential growth, leading to the formation of the Aetna Fire Insurance Company in 1819 and the Connecticut Mutual Life Insurance Co. in 1846. Throughout the 20th century, legacy carriers based in Hartford innovated across casualty, auto, and aviation lines. Today, the insurance and financial services sector contributes $15.8 billion annually to the Hartford regional economy, anchoring companies such as The Hartford, Travelers, and Cigna. Recognizing the existential threat of digital disruption, the city has aggressively fostered an InsurTech ecosystem. Organizations like InsurTech Hartford, founded in 2016, and BrokerTech Ventures act as critical conduits connecting agile startups with legacy Fortune 500 carriers, driving advancements in artificial intelligence, digital acquisition channels, and automated claims processing.

Regulatory Eligibility and Jurisprudence

A prototypical Hartford InsurTech startup developing a proprietary, machine-learning-driven underwriting platform faces a highly specific regulatory matrix under federal tax law. Because software development within the insurance industry is often perceived as administrative, it is heavily scrutinized under the Internal Use Software (IUS) regulations. Software developed primarily for general and administrative functions—such as human resources or basic financial management—must pass both the standard four-part test and an onerous three-part High Threshold of Innovation (HTI) test. The HTI test dictates that the software must be highly innovative, involve significant economic risk, and not be commercially available for use without exhaustive modification.

However, pursuant to Treasury Decision (TD) 9786, if the InsurTech firm is developing software that directly interfaces with third-party applications, or software designed to be utilized primarily by external policyholders for quoting and risk analysis, it may be exempt from the restrictive IUS classification. To satisfy the federal four-part test, the firm must demonstrate that the development of the underwriting algorithm constitutes a permitted purpose. The technological nature of the research is grounded in advanced computer science and data architecture. Technical uncertainty is established by the initial inability to determine if the neural network can accurately process unstructured environmental and demographic data to price risk. The process of experimentation must be rigorously documented through iterative code deployments, simulation runs against historical claims data, and systematic trial and error. Federal courts have repeatedly stressed the importance of contemporaneous documentation; in Moore v. Commissioner, the Tax Court ruled against the taxpayer because they failed to sufficiently document the specific activities of a key employee directly supporting the company’s research activities.

At the state level, the InsurTech firm’s engineering salaries incurred in Hartford constitute qualified research expenditures under CGS § 12-217j and § 12-217n. Assuming the firm has less than $100 million in gross revenues, it qualifies as a QSB and is entitled to the flat 6 percent non-incremental credit. If the firm operates at a net loss due to intensive capital outlays in software development, it can utilize the Connecticut Credit Exchange Program under CGS § 12-217ee. By filing Form CT-1120XCH, the firm can exchange its unused R&D credits for a cash refund equal to 65 percent of the credit’s value, providing vital non-dilutive liquidity to fund subsequent iterations of its software.

Case Study: Aerospace and Defense Manufacturing

Hartford’s dominance in aerospace manufacturing is a direct consequence of its pre-existing infrastructure in precision machining. In 1925, Frederick B. Rentschler, an aviation engineer from Ohio, sought a location with an abundance of highly skilled machinists and idle factory capacity to execute his vision of building superior aircraft engines. He found this optimal environment in Hartford, establishing the Pratt & Whitney Aircraft Company within the former Pope-Hartford automobile factory. By 1926, the company successfully designed and manufactured the R-1340 Wasp engine. Tested on a Vought 02U Corsair biplane at Hartford’s Brainard Airport, the Wasp revolutionized aviation by delivering unprecedented speed, climb performance, and reliability. During World War II, the region’s manufacturing output scaled massively to meet military demand. In the post-war era, the company successfully navigated the technological transition from internal combustion piston engines to advanced jet turbine engines. Today, as a foundational pillar of the RTX Corporation, Pratt & Whitney and its extensive supply chain support over 11,000 employees in Connecticut, representing an economic powerhouse that continuously redefines aviation engineering, fuel efficiency, and materials science.

Regulatory Eligibility and Jurisprudence

Consider an advanced aerospace component manufacturer headquartered in East Hartford, tasked with developing a novel, lightweight titanium alloy and highly automated robotic welding processes to meet next-generation commercial aircraft emission standards. The research and experimental expenditures associated with this development represent quintessential R&D under IRC Section 41. The permitted purpose is the formulation of an improved, high-strength turbine component. The research is fundamentally technological in nature, relying heavily on metallurgy, thermodynamics, and mechanical engineering. Technical uncertainty is present because it is unknown whether the experimental titanium matrix can withstand extreme thermal fluctuations without suffering catastrophic structural degradation. The process of experimentation involves casting multiple physical pilot models, subjecting them to rigorous thermal cycling, and altering the alloy ratios based on destructive testing outcomes.

In evaluating these activities, federal examiners rely heavily on established case law regarding physical prototyping. In Intermountain Electronics, Inc., the Tax Court evaluated whether the production expenses incurred to develop a pilot model qualified for the credit. The court confirmed that the physical fabrication and assembly of a custom component for testing purposes inherently constitutes a process of experimentation, provided the taxpayer satisfies the “substantially all” test by documenting the iterative lifecycle. Conversely, the aerospace manufacturer must be wary of the pitfalls highlighted in Kyocera AVX Components Corp., where the court ruled that an absence of specific documentation, a reliance on questionable estimates, and a failure to conclusively prove the process of experimentation compromises credit eligibility. Furthermore, aerospace suppliers operating under government or commercial contracts must navigate the “funded research” exclusion under Section 41(d)(4)(H). Research is considered funded—and therefore ineligible—if the taxpayer’s compensation is not strictly contingent on the success of the research, or if the taxpayer fails to retain substantial rights to the underlying intellectual property.

In Connecticut, this sector is subject to highly specialized statutory provisions. Assuming the aerospace manufacturer exceeds $200 million in annual R&D spending, it qualifies for the highest tier under CGS § 12-217n, yielding a tentative credit of $5.5 million plus 6 percent of the excess over $200 million. However, CGS § 12-217n contains a specific carve-out for aerospace companies, defining them as entities with R&D expenses exceeding $200 million in the years 1990 through 1992. These entities are legally bound by a memorandum of understanding with the Commissioner of Economic and Community Development to maintain “historical economic base functions” within the state. If an aerospace company executes significant workforce reductions by transferring operations out of Connecticut (but not out of the United States), it faces a statutory reduction in its allowable credit ranging from 10 percent to 40 percent, depending on the severity of the historical wage base reduction. Reductions exceeding 6 percent disqualify the taxpayer from receiving a certificate of eligibility entirely for that income year.

Case Study: Precision Component and Tooling Manufacturing

The foundation of Hartford’s industrial prowess lies in the American Industrial Revolution, during which the region pioneered the “American System of Manufacturing.” This paradigm shift, characterized by precision machining, interchangeable parts, and the assembly line, fundamentally altered global production methodologies. While Eli Whitney initiated the concept of interchangeable parts in neighboring regions, the true perfection of the system occurred in Hartford under Samuel Colt. In 1855, Colt constructed his massive armory on the banks of the Connecticut River, at the time the largest armory in the world. To achieve the unprecedented feat of mass-producing revolvers with 100 percent interchangeable parts, Colt hired Elisha K. Root, a mechanical genius who designed metal-stamping drop hammers, precision milling machines, and exact gauges.

This ecosystem of ingenuity bred a dense network of specialized machine shops. Hartford’s pioneer bicycle and automobile manufacturer, Pope Manufacturing, further drove demand for hyper-precise components. By 1876, the Hartford Machine Screw Company was established, eventually becoming a dominant global force in the production of automated parts, bearings, and fasteners. The profound cultural and economic significance of this industry was vividly displayed during Hartford’s “Industrial Day” parade on October 7, 1908, where 8,000 working men marched behind floats representing massive local employers like the Underwood Typewriter Company and Cheney Brothers, demonstrating the region’s total dominance in mechanical engineering. Today, this legacy survives in modern precision machine shops producing advanced, high-tolerance components for the automotive, medical, and defense sectors.

Regulatory Eligibility and Jurisprudence

A contemporary descendant of this legacy, a Hartford-based precision tooling manufacturer, initiates a project to design and build a first-of-its-kind automated packaging and assembly machine for a commercial client. The machine must operate within a Class 10,000 Clean Room environment and assemble micro-bearings with zero human intervention. The design and fabrication of this custom, automated manufacturing process qualifies for the federal R&D tax credit. The permitted purpose is the creation of a new industrial process. The research is technological in nature, relying on robotics, kinematics, and mechanical engineering. Technical uncertainty lies in determining whether the robotic actuators can achieve the required micro-tolerances at high speeds without introducing particulate contamination into the clean room. The process of experimentation involves building a physical pilot model, conducting systematic trial and error, and iteratively adjusting the programmable logic controllers (PLCs) based on real-time sensor feedback.

To successfully defend these QREs during an IRS examination, the manufacturer must thoroughly document the iterative design phases. In Phoenix Design Group, Inc. v. Commissioner, the Tax Court ruled against an engineering firm because it failed to substantiate a systematic process of evaluating alternatives; the firm could not prove that its design methodology rose above routine engineering application to constitute true experimentation. Similarly, in Little Sandy Coal v. Commissioner, the court disallowed the credit because the taxpayer failed to provide detailed documentation tying its expenditures to a definitive experimentation process. Precision manufacturers in Hartford must maintain robust records of failed prototypes, simulation logs, and CAD iterations to satisfy the “substantially all” test.

Under Connecticut state law, the wages of the mechanical engineers and the material costs consumed in building the pilot model are eligible for the 20 percent incremental credit under CGS § 12-217j, assuming current year R&E expenses exceed the preceding year’s base. The manufacturer must meticulously segregate these costs from routine operations, as CGS § 12-217j explicitly excludes expenses related to routine quality control testing once the automated machine enters commercial production. With the legislative updates implemented in 2021, the company can utilize the combined state credits to offset up to 70 percent of its corporate business tax liability, carrying any excess forward for up to 15 years, thereby reinvesting capital directly back into the local Hartford workforce.

Case Study: Biotechnology and Genomic Medicine

While Hartford’s historical strength lay in heavy manufacturing and insurance, the 21st century marked a deliberate, state-sponsored pivot toward biotechnology and the life sciences. The catalyst for this transformation was the Bioscience Connecticut initiative, a comprehensive legislative and economic development plan designed to revitalize the state’s economy by establishing a world-class bioscience cluster. The crowning achievement of this initiative in the Greater Hartford area was the recruitment of The Jackson Laboratory (JAX). Founded in Bar Harbor, Maine in 1929, JAX is a globally renowned independent biomedical research institution famous for establishing the novel concept that cancer is a genetic disorder.

Seeking to expand into the medical applications of genomics, JAX required a new facility. Recognizing the immense economic potential, the State of Connecticut provided a $192 million construction loan and $99 million in research grants to attract the institution to the UConn Health campus in Farmington, adjacent to Hartford. In 2014, The Jackson Laboratory for Genomic Medicine opened its state-of-the-art $135 million, 183,500-square-foot facility. Designed to identify the precise genetic causes of diseases and spur the development of individualized treatment plans, this facility anchored a thriving biotech cluster, attracting clinical researchers, geneticists, and a wave of supporting biotech startups to the Hartford region.

Regulatory Eligibility and Jurisprudence

Consider a venture-backed biotechnology startup, spun out of genomic research conducted near UConn Health, engaged in the preclinical development of a novel targeted biologic therapy for oncology patients. The firm utilizes recombinant DNA techniques and cellular biology to develop a small molecule pharmaceutical target. Preclinical pharmaceutical development represents the gold standard for R&D tax credit eligibility. The permitted purpose is the creation of a new therapeutic drug. The research is rooted in the biological sciences, satisfying the technological in nature requirement. Technical uncertainty is profound, as the efficacy, toxicity, and optimal cellular uptake mechanisms of the novel molecule are completely unknown at the project’s inception. The process of experimentation involves executing complex in vitro and in vivo assays, utilizing cancer avatars (mice with implanted human tumors), and analyzing genomic sequencing data to evaluate the experimental drug’s performance against alternative formulations. The supplies consumed in these laboratories—such as chemical reagents, specialized cell lines, and laboratory animals—along with the salaries of the research scientists, form a massive pool of federal QREs.

Connecticut provides uniquely aggressive administrative incentives for this specific sector. Under CGS § 12-217j, a “biotechnology company” is legally defined as an entity engaged in the business of applying technologies such as recombinant DNA techniques, biochemistry, molecular and cellular biology, genetics, and new bioprocesses to produce or modify products, or to identify targets for small molecule pharmaceutical development. The startup explicitly meets this statutory definition. (It is critical to note that the DRS enforces this definition strictly; in DRS Ruling 97-6, the department determined that a provider of routine pathology testing services did not qualify as a biotechnology company, emphasizing the requirement for true biotechnological innovation rather than routine medical testing).

Because the biotech startup is pre-revenue and incurs massive R&D expenses with no current corporate tax liability, it is the prime beneficiary of the state’s updated Credit Exchange Program. Effective January 1, 2025, under Public Act 25-168 (H.B. 7287), qualifying small biotechnology companies with less than $70 million in sales can exchange their unused R&D credits for a cash refund equal to 90 percent of the credit’s value, significantly higher than the standard 65 percent rate available to other industries. By filing Form CT-1120XCH, this startup can secure an annual refund capped at $1.5 million, providing immediate, non-dilutive liquidity that effectively acts as a state-sponsored funding mechanism to sustain ongoing clinical trials through the “valley of death” inherent in pharmaceutical development.

Case Study: Medical Device Manufacturing

The medical device manufacturing sector in the Greater Hartford region, frequently referred to as the I-91 Corridor or “Precision Valley,” is a direct evolutionary descendant of the area’s aerospace and precision tooling heritage. As the aerospace industry faced cyclical economic downturns and corporate consolidation during the late 20th century, regional contract manufacturers recognized that their extreme proficiency in precision machining, rigorous quality control, and the handling of complex alloys translated perfectly to the highly regulated medical device sector.

The Food and Drug Administration’s (FDA) stringent standards for medical instruments required the exact same micro-tolerances and exhaustive documentation protocols that the Department of Defense and aviation regulatory bodies demanded for jet engine components. Companies like Waterbury’s DiaSys Corporation and Bristol’s Beekley Corporation serve as prime examples of this successful pivot. Beekley, founded originally as a printing company in 1934, transitioned into Beekley Medical, a dedicated manufacturer researching and developing disposable medical imaging products for mammography, CT scans, and MRIs. Furthermore, the proximity to major healthcare systems in Hartford, including Hartford Hospital and UConn Health, provided immediate feedback loops for clinical validation. This dense cluster of highly trained precision machining technicians allows contract manufacturers to source 99 percent of their precision-crafted components locally, cementing the region as a premier hub for end-to-end medical device production.

Regulatory Eligibility and Jurisprudence

A specialized contract manufacturer in the Hartford area is approached by a large global medical technology firm to design the manufacturing process for a highly complex, first-of-its-kind orthopedic surgical instrument. The client provides the functional requirements of the device, but the Hartford manufacturer is solely responsible for designing the tooling, custom fixtures, and production processes required to manufacture the device at scale. The R&D undertaken by the contract manufacturer to develop this industrial process qualifies for the federal credit. The permitted purpose is the development of a new manufacturing process. It is grounded in mechanical engineering and materials science. Uncertainty exists regarding the appropriate machining techniques, tool pathing, and thermal treatments required to shape the medical-grade stainless steel without compromising its structural integrity. The process of experimentation involves utilizing Computer-Aided Design (CAD) software for simulation, executing multiple trial runs, and performing physical destructive testing (such as tensile and compression tests) on prototypes for client validation.

To successfully claim the credit, the contract manufacturer must expertly navigate the “funded research” exclusion under IRC Section 41(d)(4)(H). The contract between the manufacturer and the medical technology firm must be structured such that the manufacturer bears the economic risk of failure. If the contract is a fixed-price agreement where the manufacturer must absorb the cost of failed prototypes, the research is not funded. Furthermore, the manufacturer must retain substantial rights to the proprietary manufacturing processes and tooling developed, even if the client retains the intellectual property rights to the final medical instrument. In CPI, the Tax Court ruled against the taxpayer precisely because, for several projects, the company failed to retain substantial rights to the research results, rendering those activities ineligible under the funded research exclusion. Similarly, in Smith v. Commissioner, the IRS challenged an architectural firm under the theory that their clients funded their research via contract; the court emphasized the need to scrutinize whether contracts transfer the economic risk of failure to the taxpayer.

Under Connecticut state law, as long as the physical prototyping and process engineering occur within the state’s borders, the associated wages, supply costs (including the metal destroyed during testing), and third-party computer leasing costs for simulation software qualify for the state credits. If the manufacturer is a large enterprise zone business—employing over 2,500 people with revenues exceeding $3 billion—it is entitled to a tentative credit equal to the greater of the standard tiered calculation or 3.5 percent of total expenses under CGS § 12-217n. Furthermore, because Hartford contains 10 federally designated Opportunity Zones, medical device manufacturers locating facilities within these tracts can synergize R&D tax credits with Opportunity Zone capital investments, driving substantial private investment into the local urban core.

Case Study: Broadcast Media and Digital Technologies

Hartford has quietly cultivated a formidable presence in broadcast media and digital technology. The region serves as the operational base for major broadcast giants such as ESPN (headquartered in nearby Bristol), Entercom Communications Inc., and iHeartMedia. These entities rely on Hartford’s strategic location in the Northeast and its highly educated workforce to distribute sports, news, and entertainment globally. As media consumption has shifted from traditional linear broadcasting to digital streaming and on-demand platforms, these companies have been forced to invest heavily in software engineering, digital infrastructure, and data analytics to remain competitive.

Regulatory Eligibility and Jurisprudence

A Hartford-based digital media company initiates an R&D project to develop a proprietary, low-latency video streaming algorithm capable of dynamically adjusting bitrate based on real-time network congestion analysis. The federal R&D tax credit applies to the software development efforts required to build this platform. The permitted purpose is the creation of a new, highly efficient software architecture. The research relies fundamentally on computer science. Technical uncertainty exists because the engineering team does not know if the proposed algorithm can achieve the required latency targets across diverse mobile networks without buffering. The process of experimentation involves writing discrete blocks of code, simulating network traffic loads, and iteratively refining the data compression logic.

Because the software is developed to deliver services directly to external consumers, it bypasses the restrictive Internal Use Software (IUS) rules and the High Threshold of Innovation test, subjecting it only to the standard four-part test. To defend these claims, the digital media company must ensure rigorous time-tracking of its software engineers. As demonstrated in Moore v. Commissioner, relying on vague estimates of employee time spent on qualified activities will result in the disallowance of the credit; contemporaneous, project-based documentation is mandatory.

At the state level, the digital media company must carefully navigate the intersection of multiple incentive programs. Connecticut offers a highly lucrative Digital Media & Motion Picture Tax Credit, which provides a sliding scale credit of up to 30 percent on qualified production, pre-production, and post-production expenses incurred in the state, provided the company expends $1 million or more and conducts at least 50 percent of its principal photography or post-production within Connecticut.

The company must bifurcate its costs: expenditures related directly to content creation and media production should be routed toward the Digital Media Tax Credit, while the salaries of the computer scientists engineering the underlying streaming architecture and algorithms should be claimed as QREs under the state R&D tax credits (CGS § 12-217j and § 12-217n). By strategically isolating these expenditure pools, the media company maximizes its aggregate tax relief, offsetting up to 70 percent of its corporate business tax liability with R&D credits while simultaneously leveraging production credits for content generation.

Detailed Analysis and Strategic Implications

The interplay between federal legislation and Connecticut state tax policy provides a powerful economic catalyst for corporate entities operating within Hartford. The federal IRC Section 41 credit establishes a rigid, scientifically grounded baseline requiring comprehensive documentation of the experimentation process, the retention of economic risk, and the establishment of technical uncertainty. The recent capitalization requirements under IRC Section 174 have fundamentally altered the timing of deductions, making the immediate cash benefits of the Section 41 credit indispensable for corporate liquidity.

Simultaneously, Connecticut’s dual-credit system offers unprecedented flexibility. By allowing taxpayers to calculate benefits based on both incremental increases (CGS § 12-217j) and total state-based spending (CGS § 12-217n), the DRS ensures that both rapidly scaling startups and mature, high-spend legacy corporations receive meaningful relief. Most critically, the strategic amendments to Connecticut’s Credit Exchange Program (CGS § 12-217ee)—particularly the 90 percent exchange rate for biotechnology companies enacted under Public Act 25-168—demonstrate a targeted legislative effort to transform Hartford’s historical identity as a traditional manufacturing and insurance center into a modern locus for life sciences and high-technology enterprise.

For legacy industries like insurance and aerospace, as well as emerging sectors like InsurTech, genomic medicine, and digital media, the rigorous application of these R&D tax credits is not merely a compliance exercise. It is a fundamental component of capital strategy. By meticulously aligning technical operations with statutory definitions and evolving Tax Court jurisprudence, Hartford-based corporations can secure the non-dilutive funding necessary to ensure the continued evolution and economic vitality of the region’s industrial landscape.

The information in this study is current as of the date of publication, and is provided for information purposes only. Although we do our absolute best in our attempts to avoid errors, we cannot guarantee that errors are not present in this study. Please contact a Swanson Reed member of staff, or seek independent legal advice to further understand how this information applies to your circumstances.